ID

39958

Beskrivning

Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency; ODM derived from: https://clinicaltrials.gov/show/NCT01172431

Länk

https://clinicaltrials.gov/show/NCT01172431

Nyckelord

Versioner (1)
  1. 2020-03-06 2020-03-06 -
Rättsinnehavare

See clinicaltrials.gov

Uppladdad den

6 mars 2020

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Hypertension NCT01172431

Engelsk

Eligibility Hypertension NCT01172431

1 Formulär  
Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
creatinine clearance 30 to 90 ml/min/1.73 m2, with variations of less than 20 percent in the 2 weeks before the screening evaluation.
Beskrivning

Creatinine clearance measurement | Variation Percentage Recent

Datatyp

boolean

Alias
UMLS CUI [1]
C0373595
UMLS CUI [2,1]
C0205419
UMLS CUI [2,2]
C0439165
UMLS CUI [2,3]
C0332185
diagnosed hypertension according to guidelines or having taken anti-hypertension drugs.
Beskrivning

Hypertensive disease | Antihypertensive Agents

Datatyp

boolean

Alias
UMLS CUI [1]
C0020538
UMLS CUI [2]
C0003364
aged between 65 and 85 years.
Beskrivning

Age

Datatyp

boolean

Alias
UMLS CUI [1]
C0001779
willingness to provide written, informed consent.
Beskrivning

Informed Consent

Datatyp

boolean

Alias
UMLS CUI [1]
C0021430
ability to adhere to study protocol.
Beskrivning

Protocol Compliance

Datatyp

boolean

Alias
UMLS CUI [1]
C0525058
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
secondary hypertension.
Beskrivning

Secondary hypertension

Datatyp

boolean

Alias
UMLS CUI [1]
C0155616
diabetes mellitus.
Beskrivning

Diabetes Mellitus

Datatyp

boolean

Alias
UMLS CUI [1]
C0011849
atrial flutter/atrial fibrillation.
Beskrivning

Atrial Flutter | Atrial Fibrillation

Datatyp

boolean

Alias
UMLS CUI [1]
C0004239
UMLS CUI [2]
C0004238
symptoms of congestive heart failure (nyha iii-iv) or there is evidence that left ventricular ef < 40%.
Beskrivning

Symptoms Congestive heart failure New York Heart Association Classification | Left ventricular ejection fraction

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1457887
UMLS CUI [1,2]
C0018802
UMLS CUI [1,3]
C1275491
UMLS CUI [2]
C0428772
recent (< 6 months) myocardial infarction or cerebrovascular ischemic symptoms.
Beskrivning

Myocardial Infarction Recent | Symptoms Cerebral Ischemia

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0027051
UMLS CUI [1,2]
C0332185
UMLS CUI [2,1]
C1457887
UMLS CUI [2,2]
C0917798
recent (< 3 months) or planned coronary revascularization: pci (percutaneous coronary intervention)/cabg (coronary artery by-pass graft).
Beskrivning

Coronary revascularisation Recent | Coronary revascularisation Planned | Percutaneous Coronary Intervention | Coronary Artery Bypass Surgery

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0877341
UMLS CUI [1,2]
C0332185
UMLS CUI [2,1]
C0877341
UMLS CUI [2,2]
C1301732
UMLS CUI [3]
C1532338
UMLS CUI [4]
C0010055
severe valvular heart disease.
Beskrivning

Heart valve disease Severe

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0018824
UMLS CUI [1,2]
C0205082
history of hypersensitivity to indapamide, thiazides or to any of the components of the products.
Beskrivning

Indapamide allergy | Allergy to thiazides | Hypersensitivity Component Indapamide | Hypersensitivity Component Thiazide

Datatyp

boolean

Alias
UMLS CUI [1]
C0571927
UMLS CUI [2]
C0749320
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C1705248
UMLS CUI [3,3]
C0021186
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C1705248
UMLS CUI [4,3]
C0541746
any current condition or other disease known to interfere significantly with the absorption, distribution, metabolism or excretion of study drugs.
Beskrivning

Condition Interferes with Absorption Investigational New Drugs | Disease Interferes with Absorption Investigational New Drugs | Condition Interferes with Distribution Investigational New Drugs | Disease Interferes with Distribution Investigational New Drugs | Condition Interferes with Metabolism Investigational New Drugs | Disease Interferes with Metabolism Investigational New Drugs | Condition Interferes with Excretion Investigational New Drugs | Disease Interferes with Excretion Investigational New Drugs

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C0237442
UMLS CUI [1,4]
C0013230
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C0237442
UMLS CUI [2,4]
C0013230
UMLS CUI [3,1]
C0348080
UMLS CUI [3,2]
C0521102
UMLS CUI [3,3]
C1378698
UMLS CUI [3,4]
C0013230
UMLS CUI [4,1]
C0012634
UMLS CUI [4,2]
C0521102
UMLS CUI [4,3]
C1378698
UMLS CUI [4,4]
C0013230
UMLS CUI [5,1]
C0348080
UMLS CUI [5,2]
C0521102
UMLS CUI [5,3]
C0025519
UMLS CUI [5,4]
C0013230
UMLS CUI [6,1]
C0012634
UMLS CUI [6,2]
C0521102
UMLS CUI [6,3]
C0025519
UMLS CUI [6,4]
C0013230
UMLS CUI [7,1]
C0348080
UMLS CUI [7,2]
C0521102
UMLS CUI [7,3]
C0221102
UMLS CUI [7,4]
C0013230
UMLS CUI [8,1]
C0012634
UMLS CUI [8,2]
C0521102
UMLS CUI [8,3]
C0221102
UMLS CUI [8,4]
C0013230
participation to another investigational study in the last 3 months.
Beskrivning

Study Subject Participation Status | Research study

Datatyp

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0681814
Tillbaka till toppen

Similar models

Eligibility Hypertension NCT01172431

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
Creatinine clearance measurement | Variation Percentage Recent
Item
creatinine clearance 30 to 90 ml/min/1.73 m2, with variations of less than 20 percent in the 2 weeks before the screening evaluation.
boolean
C0373595 (UMLS CUI [1])
C0205419 (UMLS CUI [2,1])
C0439165 (UMLS CUI [2,2])
C0332185 (UMLS CUI [2,3])
Hypertensive disease | Antihypertensive Agents
Item
diagnosed hypertension according to guidelines or having taken anti-hypertension drugs.
boolean
C0020538 (UMLS CUI [1])
C0003364 (UMLS CUI [2])
Age
Item
aged between 65 and 85 years.
boolean
C0001779 (UMLS CUI [1])
Informed Consent
Item
willingness to provide written, informed consent.
boolean
C0021430 (UMLS CUI [1])
Protocol Compliance
Item
ability to adhere to study protocol.
boolean
C0525058 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Secondary hypertension
Item
secondary hypertension.
boolean
C0155616 (UMLS CUI [1])
Diabetes Mellitus
Item
diabetes mellitus.
boolean
C0011849 (UMLS CUI [1])
Atrial Flutter | Atrial Fibrillation
Item
atrial flutter/atrial fibrillation.
boolean
C0004239 (UMLS CUI [1])
C0004238 (UMLS CUI [2])
Symptoms Congestive heart failure New York Heart Association Classification | Left ventricular ejection fraction
Item
symptoms of congestive heart failure (nyha iii-iv) or there is evidence that left ventricular ef < 40%.
boolean
C1457887 (UMLS CUI [1,1])
C0018802 (UMLS CUI [1,2])
C1275491 (UMLS CUI [1,3])
C0428772 (UMLS CUI [2])
Myocardial Infarction Recent | Symptoms Cerebral Ischemia
Item
recent (< 6 months) myocardial infarction or cerebrovascular ischemic symptoms.
boolean
C0027051 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
C1457887 (UMLS CUI [2,1])
C0917798 (UMLS CUI [2,2])
Coronary revascularisation Recent | Coronary revascularisation Planned | Percutaneous Coronary Intervention | Coronary Artery Bypass Surgery
Item
recent (< 3 months) or planned coronary revascularization: pci (percutaneous coronary intervention)/cabg (coronary artery by-pass graft).
boolean
C0877341 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
C0877341 (UMLS CUI [2,1])
C1301732 (UMLS CUI [2,2])
C1532338 (UMLS CUI [3])
C0010055 (UMLS CUI [4])
Heart valve disease Severe
Item
severe valvular heart disease.
boolean
C0018824 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
Indapamide allergy | Allergy to thiazides | Hypersensitivity Component Indapamide | Hypersensitivity Component Thiazide
Item
history of hypersensitivity to indapamide, thiazides or to any of the components of the products.
boolean
C0571927 (UMLS CUI [1])
C0749320 (UMLS CUI [2])
C0020517 (UMLS CUI [3,1])
C1705248 (UMLS CUI [3,2])
C0021186 (UMLS CUI [3,3])
C0020517 (UMLS CUI [4,1])
C1705248 (UMLS CUI [4,2])
C0541746 (UMLS CUI [4,3])
Condition Interferes with Absorption Investigational New Drugs | Disease Interferes with Absorption Investigational New Drugs | Condition Interferes with Distribution Investigational New Drugs | Disease Interferes with Distribution Investigational New Drugs | Condition Interferes with Metabolism Investigational New Drugs | Disease Interferes with Metabolism Investigational New Drugs | Condition Interferes with Excretion Investigational New Drugs | Disease Interferes with Excretion Investigational New Drugs
Item
any current condition or other disease known to interfere significantly with the absorption, distribution, metabolism or excretion of study drugs.
boolean
C0348080 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0237442 (UMLS CUI [1,3])
C0013230 (UMLS CUI [1,4])
C0012634 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0237442 (UMLS CUI [2,3])
C0013230 (UMLS CUI [2,4])
C0348080 (UMLS CUI [3,1])
C0521102 (UMLS CUI [3,2])
C1378698 (UMLS CUI [3,3])
C0013230 (UMLS CUI [3,4])
C0012634 (UMLS CUI [4,1])
C0521102 (UMLS CUI [4,2])
C1378698 (UMLS CUI [4,3])
C0013230 (UMLS CUI [4,4])
C0348080 (UMLS CUI [5,1])
C0521102 (UMLS CUI [5,2])
C0025519 (UMLS CUI [5,3])
C0013230 (UMLS CUI [5,4])
C0012634 (UMLS CUI [6,1])
C0521102 (UMLS CUI [6,2])
C0025519 (UMLS CUI [6,3])
C0013230 (UMLS CUI [6,4])
C0348080 (UMLS CUI [7,1])
C0521102 (UMLS CUI [7,2])
C0221102 (UMLS CUI [7,3])
C0013230 (UMLS CUI [7,4])
C0012634 (UMLS CUI [8,1])
C0521102 (UMLS CUI [8,2])
C0221102 (UMLS CUI [8,3])
C0013230 (UMLS CUI [8,4])
Study Subject Participation Status | Research study
Item
participation to another investigational study in the last 3 months.
boolean
C2348568 (UMLS CUI [1])
C0681814 (UMLS CUI [2])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial